Cyclerion Therapeutics Stock Market Value
| CYCN Stock | USD 3.30 0.02 0.60% |
| Symbol | Cyclerion |
Cyclerion Therapeutics Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cyclerion Therapeutics. If investors know Cyclerion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cyclerion Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.08) | Revenue Per Share 0.586 | Quarterly Revenue Growth 0.141 | Return On Assets (0.47) | Return On Equity (1.50) |
The market value of Cyclerion Therapeutics is measured differently than its book value, which is the value of Cyclerion that is recorded on the company's balance sheet. Investors also form their own opinion of Cyclerion Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cyclerion Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cyclerion Therapeutics' market value can be influenced by many factors that don't directly affect Cyclerion Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cyclerion Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cyclerion Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclerion Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cyclerion Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Cyclerion Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Cyclerion Therapeutics.
| 07/01/2024 |
| 12/28/2024 |
If you would invest 0.00 in Cyclerion Therapeutics on July 1, 2024 and sell it all today you would earn a total of 0.00 from holding Cyclerion Therapeutics or generate 0.0% return on investment in Cyclerion Therapeutics over 180 days. Cyclerion Therapeutics is related to or competes with Fate Therapeutics, and Caribou Biosciences. Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and c... More
Cyclerion Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Cyclerion Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Cyclerion Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 12.63 | |||
| Information Ratio | 0.0902 | |||
| Maximum Drawdown | 326.74 | |||
| Value At Risk | (23.35) | |||
| Potential Upside | 18.75 |
Cyclerion Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cyclerion Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Cyclerion Therapeutics' standard deviation. In reality, there are many statistical measures that can use Cyclerion Therapeutics historical prices to predict the future Cyclerion Therapeutics' volatility.| Risk Adjusted Performance | 0.0824 | |||
| Jensen Alpha | 3.58 | |||
| Total Risk Alpha | 2.44 | |||
| Sortino Ratio | 0.277 | |||
| Treynor Ratio | (1.20) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Cyclerion Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Cyclerion Therapeutics Backtested Returns
Cyclerion Therapeutics is out of control given 3 months investment horizon. Cyclerion Therapeutics secures Sharpe Ratio (or Efficiency) of 0.0955, which signifies that the company had a 0.0955% return per unit of standard deviation over the last 3 months. We were able to break down twenty-eight different technical indicators, which can help you to evaluate if expected returns of 3.79% are justified by taking the suggested risk. Use Cyclerion Therapeutics mean deviation of 13.31, and Risk Adjusted Performance of 0.0824 to evaluate company specific risk that cannot be diversified away. Cyclerion Therapeutics holds a performance score of 7 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of -2.92, which signifies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Cyclerion Therapeutics are expected to decrease by larger amounts. On the other hand, during market turmoil, Cyclerion Therapeutics is expected to outperform it. Use Cyclerion Therapeutics maximum drawdown, and the relationship between the information ratio and expected short fall , to analyze future returns on Cyclerion Therapeutics.
Auto-correlation | 0.17 |
Very weak predictability
Cyclerion Therapeutics has very weak predictability. Overlapping area represents the amount of predictability between Cyclerion Therapeutics time series from 1st of July 2024 to 29th of September 2024 and 29th of September 2024 to 28th of December 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Cyclerion Therapeutics price movement. The serial correlation of 0.17 indicates that over 17.0% of current Cyclerion Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.17 | |
| Spearman Rank Test | -0.42 | |
| Residual Average | 0.0 | |
| Price Variance | 0.69 |
Cyclerion Therapeutics lagged returns against current returns
Autocorrelation, which is Cyclerion Therapeutics stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Cyclerion Therapeutics' stock expected returns. We can calculate the autocorrelation of Cyclerion Therapeutics returns to help us make a trade decision. For example, suppose you find that Cyclerion Therapeutics has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Cyclerion Therapeutics regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Cyclerion Therapeutics stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Cyclerion Therapeutics stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Cyclerion Therapeutics stock over time.
Current vs Lagged Prices |
| Timeline |
Cyclerion Therapeutics Lagged Returns
When evaluating Cyclerion Therapeutics' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Cyclerion Therapeutics stock have on its future price. Cyclerion Therapeutics autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Cyclerion Therapeutics autocorrelation shows the relationship between Cyclerion Therapeutics stock current value and its past values and can show if there is a momentum factor associated with investing in Cyclerion Therapeutics.
Regressed Prices |
| Timeline |
Pair Trading with Cyclerion Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cyclerion Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cyclerion Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Cyclerion Stock
| 0.37 | DTIL | Precision BioSciences | PairCorr |
| 0.35 | VIGL | Vigil Neuroscience | PairCorr |
| 0.32 | DNLI | Denali Therapeutics | PairCorr |
The ability to find closely correlated positions to Cyclerion Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cyclerion Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cyclerion Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cyclerion Therapeutics to buy it.
The correlation of Cyclerion Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cyclerion Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cyclerion Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cyclerion Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Cyclerion Therapeutics Correlation, Cyclerion Therapeutics Volatility and Cyclerion Therapeutics Alpha and Beta module to complement your research on Cyclerion Therapeutics. To learn how to invest in Cyclerion Stock, please use our How to Invest in Cyclerion Therapeutics guide.You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Cyclerion Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.